Access Menu

Log in via Social

Cannalytics Research Center

Cannalytics Research Center

We are a regulatory, compliance, scientific testing and analytical firm, with our focus in the cannabis industry.

Verify Investor Status to make a reservation

Deal Type


Funding Goal


Current Reservations


Minimum Reservation


Maximum Reservation


Deal Stage


Pre-money Valuation


Open Date


Closing Date


Elevator Pitch

Cannalytics is developing the standards for cannabis testing laboratories, focusing on regulatory compliance and oversight at State and Nation levels.


$24,000,000 Sales

Company Overview

Cannalytics Research Center (CRC) we are a regulatory, compliance, scientific testing and analytical firm, with our focus in the cannabis industry. We are building a Cannabis Compliance/Regulatory Laboratory Testing Infrastructure starting with our flagship testing and research facility in Branchburg, NJ. To achieve profitable operations Cannalytics has selected 4 additional locations for our Phase 1 Build out. These key markets are in dire need of additional testing laboratories, as there is a high demand and low supply for laboratory testing services. Rapid national expansion is planned in existing key markets along with future markets as legalization develops.

Cannalytics provides patients, cultivators, producers and dispensaries with valuable certified information about the safety, quality and potency of their medical/recreational cannabis products. Cannalytics has begun its operations in Lafayette, NJ 07848 corporate office with its primary DEA & FDA licensed laboratory and research center located in Branchburg, NJ 08876 in our 5,500 square feet, well-equipped biomedical testing laboratory.

Cannalytics intends to provide a comprehensive menu of services to stakeholders in the medical/recreational cannabis industry. These services will include cannabinoid profiling, microbiological screening, pesticide screening, terpene analysis, infused-product formulation charts and more, Cannalytics offers tests and services aimed to guarantee the quality and potency of all medical cannabis products. We look to establish long-lasting relationships with our clients through accurate data, quick turnaround and exemplary services.

Cannalytics Research Center has identified multiple problems within the cannabis testing industry, starting with regulation and compliance. Regulations are currently being developed on a state to state basis but there is no national standard or guideline for independent testing facilities. Cannalytics is approaching the market on a national level with international enterprise solutions.

One of the biggest areas of concern for cultivators, producers, dispensaries, and most importantly consumers is fraudulent or inaccurate testing results which has been identified in multiple states where cannabis has been legalized on a state level. Through our strategic partnerships with enterprise software developers and analytical testing equipment manufacturers, we have developed a comprehensive platform to identify and potentially eliminate fraudulent or inaccurate results which include false potency reporting.


  • Cannalytics visions became reality.

    February, 2018

Press Mentions

Key Customers & Partners



Scott Begraft
Scott Begraft
"I never want to say the words ‘I should have’. If I do it and I fail, I tried. If I do it and succeed, better for me, never go through life saying you should have. If you wanna do something, you do it”."

Previous Funding

  • $10,000 Equity
  • Raise Source: Self
  • September 2018

Frequently Asked Questions

Where will revenues come from?

Revenue platform is split between multiple platforms which include revenue from Testing Cannabis, Software Licensing, and Advertising

Risks & Disclosures

Investing in securities involves risk of loss that clients should be prepared to bear. No investment process is free of risk; no strategy or risk management technique can guarantee returns or eliminate risk in any market environment. There is no guarantee that our investment processes will be profitable. Past performance is not a guide to future performance. The value of investments, as well any investment income, is not guaranteed and can fluctuate based on market conditions. Diversification does not assure a profit or protect against loss.

Our discretionary investment management styles include equity, fixed income, and balanced (a mix of fixed income and equity) options which may be subject to some or all of the following risks.

Equity Securities Risk – Equity securities include common stocks, preferred stocks, convertible securities and mutual funds that invest in these securities. Equity markets can be volatile. Stock prices rise and fall based on changes in an individual company’s financial condition and overall market conditions. Stock prices can decline significantly in response to adverse market conditions, company-specific events, and other domestic and international political and economic developments.